Insiders Trades
Phreesia, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Apr 2026.
Phreesia, Inc.: what insiders have been doing
Every trade that managers of Phreesia, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in New York City, United States. It was founded in 2005. From 18 October 2025 to 18 October 2026, the disclosure feed for Phreesia, Inc. logged 105 filings by 16 insiders.
Purchases and sales both appear in the filings: 4 purchases (1 insider, €12.0M) and 31 sales (8 insiders, €1.3M). The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €7.1M from Pale Fire Capital SE, disclosed on 2 April 2026. On the buying side, the filings list 1 major shareholder among the declarants.
The clock since the last published purchase (2 April 2026) now reads 199 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 105 filings here. Over the whole record (from 2021), the tally stands at 4 purchases and 229 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 January 2026 lists revenue at 480.6 m USD and net income at 2.3 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
583
Thresholds
n/a
Buy Volume
€12M
4 ops. · all time
Sell Volume
€26M
229 ops. · all time
Who traded when
BuySaleDavid Linetsky28 sales
Yvonne Hui21 sales
Allison C. Hoffman18 sales
Balaji Gandhi16 sales
Evan Roberts16 sales
Amy Beth VanDuyn13 sales
+4 other insiders
Since the insiders bought
- +19.6%Entry US$9.15 · Close at T+90 US$10.94
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Phreesia, Inc. Buy (bullish), based on 15 analysts. Average price target: US$14.13.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 15,370 of 24,148 companies
42.9
score / 100
Value41
Quality45
FCF yld8.0%
Earn yld0.3%
EV/EBITDA26.5x
ROE3.1%
Gross mgn68%
Net mgn0.5%
Debt/EBITDA3.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended January 2026 · cache
US$10.75
Analyst consensus
15 analystsBuy
US$10.00Target US$14.13(+31%)US$20.00
Income statement
RevenueUS$480.6M
Gross profitUS$326.5M68% margin
EBITDAUS$29.5M6% margin
Net incomeUS$2.3M2.1% margin
Valuation
PER (trailing)63.2x
PER (forward)6.7x
P/Book1.8x
Beta0.84
Balance sheet & cash
Market capUS$667.3M
Total debtUS$102.4M
Free Cash FlowUS$54.4M
Debt / Equity18%
Profitability & ownership
ROE3.1%
ROA2.6%
% insiders6.4%
% institutions96.1%
Last declaration on 22 September 2026
Declarations583 total
4,475 shares@ US$10.420.0077% mcap0.8% of flowCommon StockSEC:0001412408-26-000244:0
7,401 shares@ US$10.420.013% mcap2.1% of flowCommon StockSEC:0001412408-26-000243:0
319 shares@ US$10.420.0005% mcap0.1% of flowCommon StockSEC:0001412408-26-000244:1
4,476 shares@ US$10.420.0077% mcap0.4% of flowCommon StockSEC:0001412408-26-000245:0
2,876 shares@ US$10.420.0049% mcap1.1% of flowCommon StockSEC:0001412408-26-000246:0
6,662 shares@ US$10.080.011% mcap1.8% of flowCommonSEC144:0001959173-26-007046
14,063 shares0Common StockSEC:0001412408-26-000235:0
8,113 shares0Common StockSEC:0001412408-26-000237:0
6,490 shares0Common StockSEC:0001412408-26-000236:0
8,113 shares0Common StockSEC:0001412408-26-000238:0
703 shares0Common StockSEC:0001412408-26-000237:1
192,000 shares0Common StockSEC:0001412408-26-000228:0
88,000 shares0Common StockSEC:0001412408-26-000229:0
43,000 shares0Common StockSEC:0001412408-26-000226:0
10,000 shares0Common StockSEC:0001412408-26-000230:1
192,000 shares0Common StockSEC:0001412408-26-000224:0
192,000 shares0Common StockSEC:0001412408-26-000230:0
108,000 shares0Common StockSEC:0001412408-26-000225:0
500,000 shares0Common StockSEC:0001412408-26-000227:0
182 shares@ US$12.280.0004% mcap0.0% of flowCommon StockSEC:0001412408-26-000205:0
377 shares@ US$10.730.0007% mcap1.1% of flowCommon StockSEC:0001412408-26-000202:0
685 shares@ US$10.730.0012% mcap1.2% of flowCommon StockSEC:0001412408-26-000203:0
937 shares@ US$10.760.0017% mcap1.2% of flowCommon StockSEC:0001412408-26-000198:0
69 shares@ US$10.760.0001% mcap0.0% of flowCommon StockSEC:0001412408-26-000199:0
1,247 shares@ US$10.920.0022% mcap1.6% of flowCommonSEC144:0001959173-26-005241
25 of 583 declarations
About Phreesia, Inc.
Phreesia, Inc. (ticker: PHR) is a U.S.-listed healthcare technology company trading on the NYSE in the United States. Founded in 2005, the company was built around a clear mission: help patients play a more active role in their care while improving the operational efficiency of healthcare providers. Over time, Phreesia has evolved into a recognized healthcare SaaS platform focused on patient intake, patient activation, payments, and workflow automation for provider organizations.
The company’s core platform is designed to digitize and streamline many of the administrative steps surrounding a patient visit, including registration, scheduling, payments, intake questionnaires, and selected clinical support workflows. Phreesia serves thousands of provider organizations across the U.S., giving it a meaningful national footprint in healthcare software. Management has stated that the platform supports roughly 180 million patient visits annually, which suggests significant scale and recurring usage across a broad client base.
Read moreShow less
From a competitive standpoint, Phreesia operates in an attractive but highly competitive niche that sits at the intersection of healthcare software, patient engagement, and revenue cycle-related solutions. Its market position is supported by an integrated product suite, deep penetration into provider workflows, and the ability to create value across the patient journey rather than through a single point solution. The company’s strategy is centered on expanding adoption within existing clients, adding adjacent capabilities, and strengthening payment-related offerings.
Recent developments have been important. In 2025, Phreesia announced the acquisition of AccessOne, a healthcare receivables financing specialist, to broaden its payment solutions portfolio and improve collections capabilities for healthcare providers. This acquisition fits the company’s broader effort to extend its platform from intake and engagement into payment optimization. In recent reporting, management also highlighted improving operating leverage and continued progress toward profitability, which is relevant for investors assessing the company’s transition from growth at all costs toward more disciplined execution.
Phreesia also remains a name to watch from a governance and market-signal perspective, as SEC Form 4 insider transaction activity can provide additional insight into management behavior and equity ownership trends. For French-speaking investors, the key takeaways are a durable U.S. healthcare software franchise, a specialized product set, and exposure to long-term digitization in the American healthcare system.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
